Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
|Articles|July 11, 2012
Cost Implications of Pertuzumab/Trastuzumab Combination
In this segment, panelists address coverage strategies health plans may utilize to finance patient access to the combination treatment.
Advertisement
Advertisement
Related to this article
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.
Advertisement
Advertisement
Trending on AJMC
1
Lymphoma Outcomes Hinge on Oncology, Not Viral Load In People With HIV
2
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
3
New Mechanism of DME Treatment Highlights Clinical Trial Updates
4
Using Complement Inhibitors in GA Comes With Pros and Cons
5